Clinical Trials
21 trialsNCT03914625 2026-05-27
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05675410 2026-05-27
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06124157 2026-05-27
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06317662 2026-05-22
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT00792948 2026-04-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00421174 2021-11-01
BMTCTN0403
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00720109 2020-04-13
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00084695 2014-01-10
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01005758 2014-01-10
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00008307 2014-01-06
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002599 2013-12-19
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00436761 2013-12-18
Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00112645 2013-07-18
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004255 2013-07-10
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00066417 2013-05-01
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00521430 2013-03-26
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
National Cancer Institute (NCI)
Phase NA Completed
NCT00003728 2011-01-21
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00053105 2009-07-07
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00069966 2009-07-07
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
National Cancer Institute (NCI)
Phase 2 Unknown